P
ostoperative scar formation is a serious problem in filtering glaucoma surgery. Current strategies to counteract scarring include local antimetabolite treatment, which is associated with severe side effects, limiting its application. 1 Therefore, additional means to safely modulate wound healing are desirable, and distinct molecular mediators of the scarring process may provide valuable targets for novel therapeutic approaches.
The cytokine TGF-␤ is a key mediator of wound healing and is critically involved in postoperative scarring.
2,3 On the cellular level, TGF-␤ drives the conversion of fibroblasts to myofibroblasts as a key step in all fibrotic processes. 4 This transdifferentiation is characterized by the de novo synthesis of ␣-smooth muscle actin (␣-SMA), 5 the incorporation of ␣-SMA into stress fibers, and the subsequent increase in cell contractility. 6, 7 Myofibroblasts are necessary for sufficient wound closure 8 but usually disappear at late stages of wound healing. 9 The persistence of myofibroblasts is associated with increased deposition of ECM proteins, 10, 11 leading to tissue fibrosis. Therefore, TGF-␤ is a major target of evolving antifibrotic strategies; approaches have been made using scavenging antibodies, 12, 13 endogenous antagonists, 14 and nucleotide-based methods. 15 Intracellular signaling pathways downstream of TGF-␤ may also offer therapeutic options, and inhibition of p38-or Rho-dependent signaling was shown to inhibit myofibroblast transdifferentiation in vitro. 16, 17 Statins inhibit the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and are widely used to decrease plasma cholesterol and lipoprotein levels with beneficial effects in occlusive vascular disease. 18, 19 Besides their effect on plasma lipid concentrations, statins influence distinct intracellular signal transduction processes. Several signaling molecules, such as Rho-family GTPases, translocate to the plasma membrane on activation. These molecules require an isoprenyl lipid anchor domain to attach to the inner leaflet of the plasma membrane and engage downstream signaling. Because isoprenyl groups are derived from cholesterol precursors, an inhibition of cholesterol precursor synthesis impedes isoprenyl-dependent signaling. 20, 21 Thus, statins also exert pleiotropic effects, such as the inhibition of Rho signaling, that are not directly related to lowering lipoprotein plasma levels. Pleiotropic effects account for a range of beneficial properties such as immunomodulation 20, 21 and enhanced nitrous oxide activity 22 observed with statin use.
Here we report that lovastatin prevents TGF-␤-induced myofibroblast transdifferentiation in human Tenon fibroblasts on a structural and functional level. This effect is specific because it is reversed by the addition of mevalonate, the product of HMG-CoA enzyme activity. Furthermore, the inhibition of geranylgeranyl transferase, but not of farnesyl transferase, blocks TGF-␤-induced ␣-SMA synthesis, suggesting the involvement of small Rho-family GTPases in the lovastatin effect. Thus, statins may provide a novel approach to counteract postoperative scarring in glaucoma surgery.
chased from Promega (Mannheim, Germany), and reverse transcriptase (Superscript II) was purchased from Invitrogen (Karlsruhe, Germany). Antibodies raised against the following proteins were used: ␣-SMA, tubulin (Sigma, St. Louis, MO), active p38 (Promega), total p38 (NEB, Frankfurt, Germany), active Smad-2/3 (Zymed/Zytomed, Berlin, Germany), total Smad-2/3 (Chemicon, Temecula, CA), conjugated goat anti-mouse (Alexa-488; Molecular Probes, Eugene, OR), and horseradish peroxidase-conjugated secondary antibodies (Jackson/Dianova, Hamburg, Germany). Recombinant TGF-␤1 was obtained from TebuBio (Offenbach, Germany) and was used at 2 ng/mL (final concentration) in all experiments. Lovastatin and mevalonate were from Sigma, and FTI 287 and GGTI 286 were purchased from Merck Biosciences (Bad Soden, Germany).
Cell Culture
Small Tenon biopsy samples were obtained during standard intraocular surgery after comprehensive information and written consent of selected patients. The tenets of the Declaration of Helsinki were followed, and institutional ethics committee approval was granted. Primary human Tenon fibroblasts (HTF) were gained as an expansion culture of the human Tenon explants and propagated in Dulbecco's modified Eagle medium (DMEM; PAA Laboratories GmbH, Pasching, Austria) supplemented with 10% heat-inactivated fetal calf serum (Biochrom, Berlin, Germany), 100 U/mL penicillin, and 100 g/mL streptomycin (both PAA Laboratories). Cells were maintained in the logarithmic growth phase. For all experiments, cells from passages 3 to 6 were used. All experiments were performed at least three times with similar results.
Lovastatin and Transferase Inhibitors
Lovastatin (Sigma) was dissolved in ethanol. It was converted from its inactive lactone form to its active dihydroxyl open acid form by the addition of 4 vol lovastatin dissolved in ethanol to 6 vol 0.1 N NaOH, incubation for 1 hour at 50°C, and subsequent neutralization with 1 N HCl to pH 7.2. Stock solutions (10 mM) of FTI 277 and GGTI 286 were prepared in dimethyl sulfoxide. The inhibitors were diluted in unsupplemented DMEM, added to the cell culture 16 hours (lovastatin) or 30 minutes (transferase inhibitors) before TGF-␤ stimulation, and were present with the stimuli as indicated.
RNA Isolation and Real-Time Reverse Transcription-Polymerase Chain Reaction
HTFs were plated in 60-mm cell culture dishes at 2 ϫ 10 5 cells/dish, serum-starved, and pretreated with vehicle, lovastatin, or lovastatin and mevalonate for 16 hours. Subsequently they were stimulated with TGF-␤ for various intervals. Total RNA was harvested using spin columns (RNeasy; Qiagen), according to manufacturer's recommendations. To eliminate contamination with genomic DNA, DNase digestion was performed for 15 minutes. First-strand cDNA was synthesized by reverse transcriptase (Superscript II; Invitrogen, Karlsruhe, Germany) at 42°C using 500 ng total RNA extract.
Real-time RT-PCR was conducted in a 96-well microtiter plate with a total reaction volume of 25 L containing 2 L of a 1:4 dilution of first-strand reaction product, 0.4 M specific upstream and downstream primers, 240 M dNTP-mix, 1ϫ reaction buffer, Taq polymerase, and SYBR-green (Sigma-Aldrich) as a fluorescent marker. Amplification of cDNA fragments and analysis were carried out (iCycler; Bio-Rad, München, Germany). Cycling conditions were initial denaturation at 95°C for 3 minutes followed by 40 cycles consisting of a 15-second denaturation interval and 1-minute intervals for annealing and primer extension at 60°C. Amplification of the housekeeping gene hypoxanthine-guanine-phosphoribosyl transferase 1 (HPRT1) mRNA transcript, which served as a normalization standard, was carried out with HPRT1 forward (GACCAGTCAACAGGGGACAT) and HPRT1 reverse (ACACTTCGTGGGGTCCTTTT) primers. Side-strand-specific primers for ␣-SMA and connective tissue growth factor (CTGF) were ␣-SMA forward (CTGTTCCAGCCATCCTTCAT), ␣-SMA reverse (CCGT-GATCTCCTTCTGCATT), CTGF forward (CCTGGTCCAGACCACA-GAGT), and CTGF reverse (TGGAGATTTTGGGAGTACGG). ␣-SMA and CTGF mRNA levels were measured as CT threshold levels and normalized with the individual HPRT1 control CT values.
Western Blot
Cells were rinsed with ice-cold PBS, and total cell protein extracts were prepared using a TNE lysis buffer (20 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100) containing phosphatase inhibitors (1 mM sodium vanadate, 50 mM NaF) and protease inhibitors (0.1% phenylmethylsulfonyl fluoride; Complete Protease Inhibitor, Roche). Protein concentrations were measured by a BCA assay (KMF, Lohmar, Germany). Ten micrograms of protein extracts were boiled in Laemmli sample buffer and subjected to SDS polyacrylamide gel electrophoresis. Proteins were transferred onto a polyvinylidene difluoride membrane (Amersham, Braunschweig, Germany) using a gel-blotting apparatus (Bio-Rad). Membranes were blocked in 3% BSA in TBST (10 mM Tris HCl [pH 7.4], 150 mM NaCl, 0.1% Tween 20) for 1 hour. Membranes were incubated with primary antibody overnight at 4°C and with a peroxidase-conjugated secondary antibody for 45 minutes at room temperature. After each incubation step, membranes were washed in TBST for 20 minutes. Peroxidase was visualized by enhanced chemiluminescence (ECL; Amersham) and exposure to ECL film (Hyperfilm; Amersham) for appropriate times.
Immunofluorescence Confocal Microscopy
Glass coverslips were coated with fibronectin (10 g/mL) for 1 hour at 37°C and washed with PBS. HTF cells were then plated in FCS-supplemented DMEM and incubated for 24 hours to allow efficient attachment. Cells were serum-deprived and pretreated with vehicle, lovastatin, or lovastatin and mevalonate for 16 hours and subsequently were stimulated with TGF-␤ (2 ng/mL) for 3 days. Cells were fixed in 2% paraformaldehyde, permeabilized in 0.2% Triton X-100, blocked in 2% normal goat serum (Jackson-Immuno, Hamburg, Germany), and labeled with primary antibody against ␣-SMA at a dilution of 1:400 in blocking buffer. Conjugated secondary antibody (Alexa-488; Molecular Probes) against mouse IgG was used at a 1:500 dilution in blocking buffer. Rhodamine-phalloidin was used to counterstain the F-actin cytoskeleton. Cells were viewed with a laser scanning confocal microscope (TCS SP-2; Leica Microsystems, Bensheim, Germany).
Fixed Collagen Gel Cultures
Experiments were conducted essentially as described by Grinnell et al. 23 Briefly, 24-well plates were precoated with 0.2% BSA (KMF) for 1 hour. HTF resuspended in DMEM supplemented with 0.2% FCS was added to a neutralized collagen solution (16 parts Vitrogen-100 [Cohesion, Invitrogen, Palo Alto, CA], 2 parts 10ϫ DMEM [Sigma], 1 part NaHCO 3 [Sigma]) in a 1:1 ratio, yielding a final concentration of 150,000 cells/mL and 1.2 mg/mL collagen.
Collagen cell suspension was added to each well and incubated at 37°C for 1 hour for polymerization. Gels were preincubated with vehicle, lovastatin, or lovastatin and mevalonate for 16 hours. After 48-hour stimulation with TGF-␤1 (2 ng/mL), gels were detached, and contraction was digitally photo-documented after 3 hours. Contraction quantification was performed using NIH image software (rsb.info.nih. gov/nih-image/Default.html).
RESULTS

Lovastatin Inhibits TGF-␤-Induced Smooth Muscle Actin Expression
To assess the effect of statins on TGF-␤-induced myofibroblast transdifferentiation, we measured TGF-␤-induced ␣-SMA mRNA (Fig. 1A) and protein (Fig. 1B ) levels in the presence or absence of lovastatin (10 M) and mevalonate (500 M), respectively. In the absence of lovastatin, TGF-␤ led to a robust (Figs. 1A, 1B) . Lovastatin strongly diminished the TGF-␤-induced increase of ␣-SMA mRNA and protein levels. Addition of mevalonate, the product of HMGCoA-reductase, reversed the lovastatin effect (Figs. 1A, 1C ).
Lovastatin Impedes TGF-␤-Induced ␣-SMA Recruitment to Stress Fibers
Incorporation of ␣-SMA into actin stress fibers is a characteristic feature of myofibroblast differentiation, enabling the cells to exert increased contractile activity. 4, 24, 25 We visualized the effect of lovastatin on TGF-␤-induced ␣-SMA recruitment by confocal immunofluorescence microscopy. In untreated control fibroblasts, predominantly cortical F-actin staining was detected with a few intracellular stress fibers and a weak diffuse cytoplasmic ␣-SMA signal 48 hours after plating on fibronectin ( Fig. 2A) . TGF-␤ induced pronounced actin stress fiber formation, with recruitment of ␣-SMA to stress fibers in approximately 50% of the cells (Fig. 2D) . In contrast, lovastatintreated cells showed a faint diffuse F-actin signal with almost no stress fibers and very weak cytoplasmic staining for ␣-SMA (Fig. 2B ). In the presence of lovastatin, TGF-␤ treatment resulted in a mild enhancement of the actin cytoskeleton with few stress fibers, but ␣-SMA incorporation into stress fibers was not observed (Fig. 2E) . Addition of mevalonate reversed the lovastatin effect, indicating a specific effect of HMG-CoA reductase inhibition. However, ␣-SMA recruitment to stress fibers was less pronounced than in TGF-␤ controls (Figs. 2C, 2F ).
Lovastatin Prevents TGF-␤-Induced Contraction in Fibroblast-Populated Collagen Gels
To explore the functional effects of lovastatin on TGF-␤-induced myofibroblast transdifferentiation, we assessed cell contractility in tethered fibroblast-populated collagen gels. HTFs were plated in neutralized collagen solution, pretreated with vehicle, lovastatin, or lovastatin and mevalonate for 16 hours, and stimulated with TGF-␤ (2 ng/mL). Two days later, the gels were released, and subsequent gel contraction was determined after 3 hours (Figs. 3A, 3B ). Untreated gels contracted to 47% of their initial size, and TGF-␤ strongly increased contractility (27% of initial gel size). Lovastatin blocked the TGF-␤-induced increase in contractility (48% of initial gel size), whereas the addition of mevalonate abolished the inhibitory effect of lovastatin (27% of initial gel size). Thus, lovastatin prevented the TGF-␤-induced emergence of a myofibroblast phenotype on structural and functional levels. This effect was mediated by specific inhibition of HMG-CoA reductase because it was reversed by the addition of the HMG-CoA product mevalonate.
Lovastatin Inhibits TGF-␤-Induced CTGF Expression
CTGF is an important mediator downstream of TGF-␤, with implications in myofibroblast transdifferentiation. 26 Its expression is induced by TGF-␤ and is increased in a rabbit model of filtering-glaucoma surgery. 27 We, therefore, examined the effect of lovastatin on TGF-␤-induced CTGF mRNA expression. TGF-␤ stimulation elicited a robust increase in CTGF mRNA, and lovastatin blocked this effect in a dose-dependent manner (Fig. 4) . The addition of mevalonate rescued CTGF mRNA expression in the presence of 40 M lovastatin.
Lovastatin Attenuates TGF-␤-Induced p38 Activation
We recently observed that p38 signaling is critical for TGF-␤-driven myofibroblast transdifferentiation. 16 To investigate a possible effect of lovastatin on TGF-␤-dependent signal transduction, we studied p38 and Smad-2/3 activation in the presence of lovastatin at various concentrations. TGF-␤ induced phosphorylation of a small p38 isoform (Fig. 5A, arrow) after 24 and 48 hours that was attenuated by lovastatin in a dosedependent manner. The activation of p38 at 24 hours was slightly reduced in the presence of 10 M lovastatin. At concentrations of 20 M and 40 M, lovastatin significantly blocked p38 activation (Fig. 5A) . In contrast, sustained Smad-2/3 phosphorylation at 24 hours was unaffected by lovastatin, even at 40 M. In addition, nuclear translocation of Smad-2/3 on TGF-␤ stimulation, another characteristic for activated SMAD signaling, was not altered by lovastatin (Figs. 5B-E) .
Geranylgeranyl Transferase Inhibitors, but Not Farnesyl Transferase Inhibitors, Block TGF-␤-Induced ␣-SMA Expression
To gain further insight into the possible mechanism of lovastatin-mediated inhibition of myofibroblast transdifferentiation, we studied the contribution of different posttranslational protein prenylation pathways. Statins block mevalonate synthesis and impede the synthesis of cholesterol and other isoprenoid derivatives, such as geranylgeranyl pyrophosphate or farnesyl pyrophosphate, which serve as lipid anchors for small G-proteins. Geranylgeranyl pyrophosphate is attached to Rho-family GTPases essential in cytoskeletal signaling and intracellular membrane transport. Posttranslational isoprenylation is mandatory for their proper functioning. 28 Inhibition of geranylgeranyl transferase by a specific inhibitor (GGTI 286) caused a dose-dependent decrease of TGF-␤-induced ␣-SMA expression (Fig. 6) , whereas inhibition of farnesyl transferase using FTI-277 had no effect (Fig. 6 ). Given that Rho-GTPase signaling is critical in TGF-␤-driven myofibroblast transdifferentiation, 17 this result suggests a block of Rho-geranylgeranylation as a relevant mechanism.
DISCUSSION
Subconjunctival scarring remains the most severe problem in filtering glaucoma surgery. Conversion of fibroblasts to myofibroblasts, the cellular protagonists of fibrosis, requires the cytokine TGF-␤ and cellular contractility. 17 Recent studies highlight the significance of pleiotropic effects of statins, such as inhibition of Rho-GTPase signaling, with subsequent cytoskeletal relaxation distinct from the effects on plasma cholesterol and lipoprotein levels. 29 In light of these findings, we assessed the effect of lovastatin on TGF-␤-induced myofibroblast transdifferentiation. Our data indicate that lovastatin blocks this process in human Tenon fibroblasts by the inhibition of posttranslational isoprenylation.
To evaluate a possible influence of statins on TGF-␤-induced structural changes in human Tenon fibroblasts, we first assessed the expression of the myofibroblast marker ␣-SMA. Lovastatin inhibited the TGF-␤-induced expression of ␣-SMA on mRNA and protein levels (Figs. 1A, 1B) . In the presence of lovastatin, TGF-␤-induced ␣-SMA expression was rescued by the addition of mevalonate, the product of HMG-CoA reductase (Figs. 1A, 1C ). This result suggests that the blocking effect of lovastatin is caused by specific inhibition of mevalonate synthesis rather than other known possible mechanisms, such as extracellular binding to adhesion molecules. 30 Our data are supported by other studies reporting the inhibition of TGF-␤-induced ␣-SMA expression in atrial fibroblasts 31 and lung fibroblasts. 32 Moreover, ␣-SMA expression seen in renal interstitial fibrosis after unilateral urethral obstruction in a rat model was reduced by statin application. 33 In addition to the protein expression level, the subcellular localization of ␣-SMA is critical for the acquisition of a myofibroblast phenotype because ␣-SMA recruitment to actin stress fibers is required to enhance cell contractility. 34 Therefore, we studied ␣-SMA localization by confocal immunofluorescence microscopy. Lovastatin blocked the TGF-␤-induced incorporation of ␣-SMA into actin stress fibers (Fig. 2D ) and prevented enhancement of the F-actin cytoskeleton. Both these effects were reversed by the addition of mevalonate (Fig. 2F) .
To explore the influence of lovastatin in a functional assay, we measured the contraction of tethered fibroblast-populated collagen gels. 35 Increased gel contraction exerted by TGF-␤-treated fibroblasts was abrogated by lovastatin and rescued by additional application of mevalonate (Fig. 3) . Consistent with these findings, the inhibition of TGF-␤-induced gel contraction by lovastatin has been observed in kidney 36 and lung fibroblasts. 32 CTGF acts as an important mediator of scarring processes downstream of TGF-␤. 37 In addition to its effects on SMA expression, lovastatin also inhibited TGF-␤-induced CTGF expression (Fig. 4) . These results are in line with previous observations in renal and lung fibroblasts. 32, 38 Next, we focused on the influence of lovastatin on TGF-␤-mediated signal transduction. Lovastatin reduced TGF-␤-induced p38 activation, whereas Smad-2/3 phosphorylation and nuclear translocation were unaffected (Fig. 4) . These data are reminiscent of the effects observed with inhibitors of the Rho-dependent kinase ROCK, which blocked cell contraction, p38 activation, and ␣-SMA expression to inhibit myofibroblast transdifferentiation, 17 suggesting a related mechanism of action. Several pleiotropic effects of statins were attributed to an inhibition of Rho-GTPase signaling: Lovastatin impaired HIV entry into mononuclear blood cells by blocking Rho signaling. 39 Similarly, statins blocked plasma membrane translocation of Rho in cardiac myofibroblasts, 40 and the TGF-␤-induced expression of CTGF and ␣-SMA by inhibiting Rho function. 32, 38 In the eye, statins were shown to induce trabecular meshwork cell relaxation and a hypotensive response in an anterior chamber perfusion model by interfering with Rho-GTPase function. 41 These pleiotropic statin effects are attributed mainly to interference with mevalonate-dependent isoprenoid metabolism. 20, 21 The isoprenoids geranylgeranyl pyrophosphate and farnesyl-pyrophosphate serve as lipid anchor domains and allow protein attachment to the inner leaflet of the plasma membrane. Posttranslational addition of a geranylgeranyl domain is mandatory for the correct localization and function of the small GTPase Rho, which is a master regulator of the actin cytoskeleton and governs cell contractility. 28 In our system, the effect of lovastatin was mimicked by the inhibition of geranylgeranyl transferase, which averted TGF-␤-induced ␣-SMA expression, whereas the inhibition of farnesyl transferase had no effect. These data are compatible with a lovastatin-induced inhibition of Rho signaling in human Tenon fibroblasts.
Several beneficial ocular effects of statins have been suggested: statins reduce the risk for nuclear cataracts 42, 43 and the development of indistinct soft drusen, 44 and they may have the potential to decrease outflow resistance. 41 Our data indicate that lovastatin prevents TGF-␤-induced myofibroblast transdifferentiation in human Tenon fibroblasts in vitro. This effect is mediated by specific inhibition of mevalonate synthesis and most likely the result of a subsequent block of Rho-GTPase isoprenylation. Statins may, therefore, serve as safe adjuvant drugs to modulate wound healing and to prevent postoperative scarring after filtering glaucoma surgery. 
